Total Alpha Synuclein (Total Α Syn) Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property |
Value |
| Category |
Protein Biomarker |
| Target |
Total alpha-synuclein (canonical + aggregated) |
| Sample Type |
CSF, plasma, serum |
| Diseases |
Parkinson's Disease, Dementia with Lewy Bodies, Multiple System Atrophy, Alzheimer's Disease |
| Clinical Use |
Diagnosis, disease progression, treatment response |
Total alpha-synuclein refers to all forms of alpha-synuclein protein in biological samples, including monomeric, oligomeric, and aggregated species. Unlike phosphorylated alpha-synuclein (pSer129) which specifically detects pathologically aggregated forms, total alpha-synuclein measures the overall protein concentration regardless of its aggregation state.
Alpha-synuclein is a 140-amino acid protein encoded by the SNCA gene located on chromosome 4q21. It is abundantly expressed in the brain, particularly in presynaptic terminals. The protein contains three domains:
- N-terminal domain (1-60): Charged repeats that mediate membrane binding
- Central hydrophobic region (61-95): Non-Aβ component (NAC) crucial for aggregation
- C-terminal domain (96-140): Acidic region involved in protein-protein interactions
| Domain |
Amino Acids |
Key Features |
| N-terminal |
1-60 |
7 repeats of 11 residues, membrane binding |
| NAC |
61-95 |
Hydrophobic, aggregation-prone |
| C-terminal |
96-140 |
Acidic, chaperone-like activity |
In healthy brains, alpha-synuclein plays important roles:
- Synaptic vesicle regulation: Modulates neurotransmitter release
- Molecular chaperone activity: Helps maintain protein homeostasis
- ** lipid metabolism**: Associates with synaptic membranes
- Antioxidant protection: Scavenges reactive oxygen species
The protein exists predominantly as an unstructured monomer in the cytosol but can adopt alpha-helical structure upon membrane binding.[1]
- Most common clinical method
- Sensitivity: 10-100 pg/mL
- Commercial kits: Euroimmun, BioLegend, Abcam
- Measures total protein concentration
- Ultra-sensitive digital immunoassay
- Detects very low concentrations in plasma
- Higher sensitivity than conventional ELISA
- Enables blood-based biomarker detection
- Automated chemiluminescent assay
- FDA-approved for CSF testing
- High precision and reproducibility
- Standardized for clinical use
- Western blot: Detects specific aggregation states
- Immunoprecipitation-mass spectrometry: Quantifies specific species
- Real-time quaking-induced conversion (RT-QuIC): Detects seeding activity
- Diagnostic utility: Reduced CSF total α-syn compared to healthy controls
- Sensitivity: 70-90% in early PD
- Specificity: 50-70% (overlaps with other neurodegenerative diseases)
- Progression marker: Levels decrease with disease progression
- Motor subtypes: More severe reduction in postural instability/gait difficulty (PIGD) subtype
- Similar pattern to PD but often more severe reduction
- Can help differentiate from Alzheimer's disease
- Correlates with cognitive decline severity
- Useful in distinguishing DLB from AD
- More severe reduction than PD
- May help differentiate parkinsonian subtypes
- Sensitivity for MSA: 80-90%
- Specificity vs PD: 60-70%
- Less affected than synucleinopathies
- Can be elevated in some cases
- May show combined pathology (AD + DLB)
- Useful in differential diagnosis
- Loss of dopaminergic neurons leads to release of α-syn into CSF
- Increased extracellular α-syn may reflect neuronal death
- Aggregation into oligomers and fibrils is pathogenic
- The α-synucleotide hypothesis proposes extracellular release followed by neuronal uptake and propagation
- Widespread Lewy body pathology throughout cortex
- Earlier and more severe neuronal loss
- Strong correlation with visual hallucinations
- Both cortical and subcortical involvement
- Oligodendroglial pathology (glial cytoplasmic inclusions)
- More dramatic CSF reduction due to oligodendrocyte involvement
- Different pattern of regional vulnerability
- Primary oligodendropathy vs secondary
| Factor |
Recommendation |
| Collection tube |
Polypropylene |
| Centrifugation |
2000 x g, 10 min, 4°C |
| Storage |
-80°C, avoid freeze-thaw |
| Volume needed |
500 μL minimum |
- Room temperature: 2-4 hours
- 4°C: 24-48 hours
- -20°C: 1-2 weeks
- -80°C: Long-term (years)
- Blood contamination: Increases total α-syn
- Traumatic LP: Exclude samples with RBC > 500/μL
- Diurnal variation: Limited evidence
- Exercise: May transiently increase
| Population |
CSF α-syn (ng/mL) |
| Healthy controls |
1.5-3.0 |
| Parkinson's disease |
0.8-1.5 |
| DLB |
0.6-1.2 |
| MSA |
0.5-1.0 |
| AD |
1.2-2.2 |
Note: Ranges vary by assay manufacturer
- Rule in synucleinopathy: Total α-syn < 1.0 ng/mL suggests synucleinopathy
- Differentiate subtypes: MSA shows lowest levels, more severe than PD
- Combine with other biomarkers: pSer129, tau, Aβ improve accuracy
- Clinical correlation essential: Cannot replace clinical assessment
| Biomarker |
Target |
Clinical Utility |
| Total α-syn |
All forms |
Disease diagnosis |
| pSer129 |
Phosphorylated (aggregated) |
Pathology detection |
| Oligomeric α-syn |
Toxic oligomers |
Disease progression |
| α-syn seeding |
Propagation capacity |
Early detection |
- Immunotherapies: Anti-α-syn antibodies may affect CSF levels
- Small molecules: Effects on protein clearance
- Gene therapy: SNCA expression modulation
- Levodopa: No significant effect on total α-syn
- Dopamine agonists: Limited data
- MAO-B inhibitors: Under investigation
- Overlap between diseases: Not perfectly specific
- Variable cutoffs: Different assays, different populations
- Preanalytical sensitivity: Requires careful sample handling
- Blood-brain barrier penetration: CSF more reliable than blood
- Not disease-specific within synucleinopathies
- Seeding assays: RT-QuIC, PMCA for early detection
- Single-molecule detection: Identify specific species
- Multiplex platforms: Measure multiple α-syn forms
- Use as enrollment biomarker
- Pharmacodynamic marker
- Disease progression marker
The study of Total Alpha Synuclein (Total Α Syn) Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Spillantini MG, et al. (1997). α-Synuclein in Lewy bodies. Nature. 388(6645): 839-840.
- Tokuda T, et al. (2006). Detection of elevated α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology. 67(3): 420-422.
- Mollenhauer B, et al. (2011). α-Synuclein and tau concentrations in cerebrospinal fluid of patients with Parkinson's disease. Movement Disorders. 26(3): 332-338.
- Hall S, et al. (2012). Accuracy of a panel of 5 cerebrospinal fluid biomarkers for diagnosis of sporadic Creutzfeldt-Jakob disease. JAMA Neurology. 69(10): 1264-1270.
- Parnetti L, et al. (2019). Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force. Alzheimer's & Dementia. 15(9): 1169-1194.
¶ Biomarker Panels and Combination Testing
For comprehensive assessment of synucleinopathies, combine:
| Biomarker |
Primary Information |
| Total α-syn |
Overall neuronal integrity |
| pSer129 |
Pathological aggregation |
| NFL |
Neurodegeneration severity |
| Tau |
Co-pathology (AD) |
PD vs MSA vs DLB:
- MSA: Lowest total α-syn, severe reduction
- DLB: Moderate reduction, cortical pattern
- PD: Variable reduction, subcortical pattern
With Alzheimer's:
- Add Aβ42/40 ratio
- Add phosphorylated tau
- Helps identify mixed pathology
- Gene duplication: Increased total α-syn production
- Triplication: Severe early-onset PD
- CSF patterns: May show elevated α-syn
| Mutation |
Effect on Biomarkers |
| A53T |
Earlier onset, faster progression |
| E46K |
Increased aggregation |
| H50Q |
Variable effects |
- Healthy elderly: ~10-15% have abnormal total α-syn
- Early PD: 70-80% have reduced levels
- At-risk populations: Family members may show intermediate changes
- Age: Gradual decline in healthy controls
- Genetics: SNCA variants affect levels
- Environmental: Pesticide exposure associations
¶ Laboratory Standards
- Internal QC: Pooled control samples
- External QC: Proficiency testing programs
- Standardization: IFCC working groups
- Precision: CV < 10%
- Accuracy: Recovery 85-115%
- Linearity: Across reportable range
¶ Sensitivity and Specificity
| Condition |
Sensitivity |
Specificity vs HC |
| PD |
80% |
65% |
| DLB |
85% |
70% |
| MSA |
90% |
60% |
HC = Healthy Controls
¶ Positive and Negative Predictive Values
In a population with 50% pre-test probability:
- Simoa enables plasma detection
- Correlation with CSF moderate
- Promising for screening
- Lateral flow assays under development
- Rapid results needed for clinical use
- Currently research use only
- Subtype-specific biomarkers
- Treatment response prediction
- Personalized monitoring
- Initial presentation: Motor symptoms + clinical exam
- Biomarker testing: CSF analysis including total α-syn
- Imaging: DaTscan if needed
- Integration: Clinical + biomarker + imaging
- Serial CSF sampling every 1-2 years
- Track changes over time
- Correlate with clinical scores (MDS-UPDRS)
- No cleared test for total α-syn
- Lumipulse has FDA clearance for other biomarkers
- Research use only currently
- Several CE-marked ELISA kits available
- IVD certified for clinical use in EU
- CSF analysis: 50-300 per test
- Commercial kits: Variable pricing
- Not covered by most insurance
- Earlier diagnosis enables earlier treatment
- May reduce diagnostic workup costs
- Clinical trial utility drives development
Total alpha-synuclein in CSF is a valuable biomarker for:
- Diagnosis: Helps identify synucleinopathies among parkinsonian disorders
- Differential diagnosis: Aids in PD vs MSA vs DLB distinction
- Disease monitoring: Declines with progression
- Research: Essential for clinical trials
Limitations include:
- Moderate specificity
- Preanalytical requirements
- Need for assay standardization
The biomarker is recommended as part of a comprehensive panel including pSer129, tau, and Aβ42/40 for optimal clinical utility.
- Limited data on pediatric reference ranges
- Generally higher levels than adults
- Not recommended for pediatric neurological conditions
- No significant changes observed
- Limited studies available
- Continue standard interpretation
- May affect biomarker metabolism
- Consider co-morbidities in interpretation
- Limited data available
| Marker |
Primary Use |
Sample |
Strengths |
| Total α-syn |
Synucleinopathies |
CSF |
Direct disease relevance |
| NfL |
All neurodegeneration |
CSF/Blood |
High sensitivity |
| Tau |
AD |
CSF |
AD-specific |
| p-tau |
AD |
CSF |
High specificity |
Multi-marker approaches improve diagnostic accuracy:
Parkinsonism panel:
- Total α-syn + pSer129 + NfL + tau
Dementia panel:
- Total α-syn + Aβ42/40 + p-tau + NfL
- Changes detectable in premotor phase
- Potential for prodromal identification
- High-risk population screening
- Enrollment biomarker (synucleinopathy confirmation)
- Pharmacodynamic marker
- Outcome measure (progression)
- Post-translational modifications
- Specific oligomeric species
- Cell-type specific signatures
- Clinical indication: Suspicion of synucleinopathy
- Pre-test counseling: Explain limitations
- Sample collection: Standardized LP procedure
- Result interpretation: With specialist input
Low total α-syn:
- Suggests synucleinopathy
- Correlate with clinical findings
- Consider additional testing
Normal total α-syn:
- Does not exclude synucleinopathy
- May be early disease
- Clinical correlation essential
Elevated total α-syn:
- Rare, consider contamination
- Review sample quality
- Possible acute neuronal injury
¶ Education and Resources
- Explanation of lumbar puncture
- Understanding biomarker results
- Implications for diagnosis and treatment
- Interpretation guidelines
- Test ordering information
- Correlation with clinical assessment
- Standard operating procedures
- Assay validation protocols
- Data sharing initiatives
- Parkinson's Progression Markers Initiative (PPMI): Standardized biomarker collection
- Michael J. Fox Foundation: Research priorities
- Alzheimer's Disease Neuroimaging Initiative (ADNI): Expanded to include synuclein
- Common data elements
- Standardized protocols
- Multi-center validation
Total alpha-synuclein represents a cornerstone biomarker in the evaluation of suspected synucleinopathies. While not perfect in isolation, when combined with clinical assessment and other biomarker modalities, it provides valuable diagnostic and prognostic information. Ongoing research continues to refine its clinical utility and develop improved detection methods.